Search results

Balancing risk to optimise reward

Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation.

https://oxb.com/investors/researches/balancing-risk-optimise-reward

Harnessing the CAR-T

Over the past year, Oxford BioMedica’s outlook has been transformed.

https://oxb.com/investors/researches/harnessing-car-t

New non-dilutive funding to expand production

Oxford BioMedica has secured a $50m loan facility from Oberland Capital.

https://oxb.com/investors/researches/new-non-dilutive-funding-expand-production